Marincek B, Young S W, Enzmann D R
Invest Radiol. 1982 Jan-Feb;17(1):90-4. doi: 10.1097/00004424-198201000-00017.
Iosulamide meglumine, a new intravenous biliary contrast agent, was evaluated as a potential hepatic contrast agent utilizing computed tomographic scanning. Time-density data in dogs were generated following 56.7 and 75.6 mg iodine/kg body weight. The iodine was administered both as an iosulamide meglumine bolus injection and a 0.77 ml/min infusion. The greatest increase in x-ray attenuation (24 HU) was observed within 45 minutes after the 75.6 mg iodine/kg body weight infusion technique, which resulted in excellent hepatic opacification. The long duration of increased x-ray attenuation of hepatocytes produced by iosulamide meglumine would be useful in the CT detection of hepatic mass lesions which do not contain normally functioning hepatic cells.